Tirzepatide doses run from 2.5 mg to 15 mg weekly, in six FDA-approved steps. The 2.5 mg level is a starter step meant to reduce nausea; the remaining five levels (5, 7.5, 10, 12.5, and 15 mg) are the potential maintenance range. Clinicians escalate every four weeks as tolerated, and the right long-term dose varies by person.
The Six FDA-Approved Dose Levels
Both brand names of tirzepatide — Mounjaro for type 2 diabetes and Zepbound for chronic weight management — share the same six-step dose ladder. Each step corresponds to a distinct single-dose pen with its own color and labeling, reducing the chance of medication errors.
| Dose | Role | Typical Timing |
|---|---|---|
| 2.5 mg | Starter — not maintenance | Weeks 1 to 4 |
| 5 mg | First maintenance-capable dose | Weeks 5 to 8 |
| 7.5 mg | Optional step-up | Weeks 9 to 12 |
| 10 mg | Common maintenance target | Weeks 13 to 16 |
| 12.5 mg | Additional step if needed | Weeks 17 to 20 |
| 15 mg | Maximum labeled dose | Weeks 21 onward |
This timeline assumes smooth tolerance. Many people spend longer at one or two steps before escalating. For broader perspective on where tirzepatide fits relative to other options, see our treatment hub.
How Clinicians Decide on the Maintenance Dose
In the SURPASS trials for type 2 diabetes, higher doses produced greater A1C reductions — roughly a 2.0 percent drop at 10 mg and about 2.2 percent at 15 mg in populations with baseline A1C near 8.0 percent. The SURMOUNT obesity trials showed similar dose-response: approximately 15 percent weight loss at 5 mg, 19.5 percent at 10 mg, and 20.9 percent at 15 mg over 72 weeks.
But averages mask wide individual variation. Some people achieve excellent A1C control at 5 mg; others require the full 15 mg. Side-effect tolerance is often the deciding factor. Your clinician weighs efficacy, side effects, comorbidities, and your broader nutrition and activity context.
Common Reasons to Slow or Pause Titration
- Persistent nausea or vomiting that interferes with daily function.
- Severe constipation or diarrhea not controlled with conservative measures.
- Signs of dehydration — lightheadedness, reduced urine output, confusion.
- Symptoms suggestive of pancreatitis or gallbladder disease.
- Upcoming planned procedures requiring gastrointestinal preparation.
Side Effects by Dose
According to the FDA prescribing information, gastrointestinal side effects occur at all doses but tend to be more frequent and more intense at higher doses. Rare but serious risks — pancreatitis, gallbladder disease, acute kidney injury from dehydration, diabetic retinopathy complications, severe hypersensitivity — are listed across the full dose range. The boxed warning about thyroid C-cell tumors applies regardless of dose.
Restarting After an Interruption
If you miss a dose by more than four days, or have paused for longer, the FDA label advises restarting at a lower step rather than resuming at the prior dose. This reduces the chance of a severe nausea relapse. The specific restart dose depends on how long the interruption lasted and your tolerance history — again, a decision for your prescriber.
Long-Term Considerations
GLP-1 receptor agonist therapy, including tirzepatide, is generally conceived as a long-term treatment when used for chronic conditions. Clinical data suggest weight regain and A1C rebound after discontinuation, which is why some people remain on a steady dose indefinitely once goals are reached. Periodic reassessment — typically every three to six months — evaluates whether the current dose still matches your situation.
Practical Tips for Each Dose Step
Many clinicians suggest consistent weekly timing — for example, the same weekday and roughly the same time of day. Rotating injection sites (abdomen, thigh, upper arm) reduces injection-site reactions. Eating smaller, lower-fat meals around dose escalation weeks often tames nausea. Staying well hydrated protects against the dehydration that can follow vomiting or diarrhea. Patients who take oral medications that depend on timing — thyroid hormone, certain antibiotics, oral contraceptives — should review absorption concerns with their prescriber, since tirzepatide slows gastric emptying throughout the dosing cycle.
The Bottom Line
Tirzepatide doses span a six-step ladder designed to balance efficacy with tolerability. The maintenance dose that is right for another person may not be right for you. Use this overview as a reference framework for conversations with your clinician; actual starting doses, escalations, pauses, and stopping decisions should be made together with the prescriber and pharmacist who know your medical history, medications, and goals.
